Abstract
With the US Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) screening for prostate cancer1 and conservative guidance from other national panels,2-4 the future of PSA screening is uncertain. The recently updated guidelines relied heavily on results from 2 large trials conducted in the United States and Europe.5-7 These results have been interpreted by some as demonstrating that PSA screening provides at most modest benefit, with unacceptable costs in terms of overdiagnosis and overtreatment.8,9 However, for a long-term horizon, the number of lives saved by screening is likely to be considerably higher and the fraction of overdiagnosed patients is likely to be considerably lower compared with those of the trials.10-13 Rather than rejecting screening, additional studies13,14 have recommended seeking more personalized (or “smarter”) screening strategies that preserve benefit while reducing harm. Unfortunately, these strategies are unlikely to be evaluated in randomized clinical trials owing to resource and logistic constraints. Therefore, we have used modeling to conduct simulated comparisons of candidate screening approaches.

This publication has 55 references indexed in Scilit: